BioSpace News Archive

Faruqi & Faruqi, LLP reminds investors in Alnylam Pharmaceuticals, Inc. of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Further validation of minimally-invasive monitor of celiac villous intestinal health

The newly published study explored the association of genetic predisposition to Alzheimer’s disease with cardiometabolic risk factors in 469 primary school children in Kuopio, Finland, during a two-year follow-up.

Hyperacute serum therapy: pilot first-in-man results in knee osteoarthritis

Announces Notice of Allowance of US Patent for IL-2 Superkine Agonists and Antagonist

FLX Bio, Inc., a clinical-stage, biopharmaceutical company, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers.

ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 RESET CeD trial for the treatment of celiac disease.

ANI Pharmaceuticals, Inc. announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City.

Neurotrope, Inc. today announced that Dr. Charles Ryan, Neurotrope’s Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time.

ety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial